Literature DB >> 25808023

Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.

D E Coutant1, P Kulanthaivel1, P K Turner2, R L Bell2, J Baldwin2, S R Wijayawardana3, C Pitou2, S D Hall1.   

Abstract

The human inflammatory response can result in the alteration of drug clearance through effects on metabolizing enzymes or transporters. In this article we briefly review the theory of how cancer can lead to indirect changes in drug metabolism, review acute phase proteins and cytokines as markers of changes in cytochrome P450 (CYP) activity in cancer patients, and provide clinical case examples of how the inflammation in advanced cancer patients can lead to altered CYP-mediated drug clearance.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25808023     DOI： 10.1002/cpt.128

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  21 in total

1.  Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.

Authors:  Carlos Fernandez-Teruel; Ignacio Gonzalez; Iñaki F Trocóniz; Rubin Lubomirov; Arturo Soto; Salvador Fudio
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

Review 2.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

3.  Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.

Authors:  Ying Ou; Yang Xu; Lia Gore; R Donald Harvey; Alain Mita; Kyriakos P Papadopoulos; Zhengping Wang; Richard E Cutler; Dawn E Pinchasik; Apostolia M Tsimberidou
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

4.  Hepatic ameliorative role of vitamin B17 against Ehrlich ascites carcinoma-induced liver toxicity.

Authors:  Ehab Tousson; Ezar Hafez; Maha Mohamed Abo Gazia; Siham Bayomi Salem; Thulfiqar Fawwaz Mutar
Journal:  Environ Sci Pollut Res Int       Date:  2020-01-08       Impact factor: 4.223

5.  A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.

Authors:  Shinji Iwasaki; Andy Zhu; Michael Hanley; Karthik Venkatakrishnan; Cindy Xia
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

6.  Supportive care medications coinciding with chemotherapy among children with hematologic malignancy.

Authors:  Eman Biltaji; Elena Y Enioutina; Venkata Yellepeddi; Joseph E Rower; Catherine M T Sherwin; Robert M Ward; Richard S Lemons; Jonathan E Constance
Journal:  Leuk Lymphoma       Date:  2020-04-07

7.  A Semi-Physiologically Based Pharmacokinetic Model Describing the Altered Metabolism of Midazolam Due to Inflammation in Mice.

Authors:  Ninad Varkhede; Nita Patel; William Chang; Kenneth Ruterbories; M Laird Forrest
Journal:  Pharm Res       Date:  2018-06-21       Impact factor: 4.200

8.  Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: A new strategy for CYP3A-mediated drug hepatotoxicity.

Authors:  Jiali Liu; Xiaoliang Jin; Fang Zhou; Hongzhu Chen; Wenjie Wang; Yan Liu; Guangji Wang; Kun Hao; Jingwei Zhang
Journal:  Br J Pharmacol       Date:  2020-01-29       Impact factor: 8.739

9.  Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer.

Authors:  Kathryn Brown; Craig Comisar; Han Witjes; John Maringwa; Rik de Greef; Karthick Vishwanathan; Mireille Cantarini; Eugène Cox
Journal:  Br J Clin Pharmacol       Date:  2017-02-06       Impact factor: 4.335

10.  Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.

Authors:  Kun Wang; Xueting Yao; Miao Zhang; Dongyang Liu; Yuying Gao; Srikumar Sahasranaman; Ying C Ou
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.